Tag:
lixisenatide
Latest Headlines
Latest Headlines
Buzz: Amylin brings in the bankers to spur an auction
Amylin has never confirmed or denied the much repeated story that it rejected a $22 per share bid for the company by Bristol-Myers Squibb.
Sanofi adds to growing cache of positive PhIII lixisenatide data
Sanofi ( $SNY ) is adding another fresh set of positive late-stage data for its diabetes drug hopeful lixisenatide , which has been submitted for approval in Europe and is headed to FDA regulators in
Sanofi lines up a growing slate of late-stage drug prospects
Few Big Pharma companies have done as much as Sanofi to change the game plan in R&D. And if you drill down into the company's second quarter report today, you'll find a snapshot of just how
Sanofi touts promising Ph3 results for blockbuster diabetes program
Sanofi clearly impressed analysts with a new round of promising Phase III results on lixisenatide, its GLP-1 drug for diabetes. Sticking with the headline results for now, investigators reported that
Sanofi's lixisenatide aces Phase III
Sanofi-Aventis says a late-stage trial of its experimental diabetes drug lixisenatide help cut blood sugar, body weight and glucose. The drug, which belongs to the GLP-1 class, is just one program
Sanofi GLP-1 diabetes drug edges Byetta in Phase III study
Building up its war chest of positive data for the Type 2 diabetes drug lixisenatide, Sanofi-Aventis has hit another primary goal in a late stage study: Non-inferiority to Byetta (exenatide) for
Zealand Pharma tests chilly IPO waters
A Danish newspaper is reporting that Zealand Pharma--the biotech responsible for initially developing the late-stage diabetes drug lixisenatide and then licensing it to Sanofi--is poised to launch an
Sanofi's GLP-1 drug hits promising marks in PhIII diabetes trial
Sanofi-Aventis' GLP-1 diabetes drug lixisenatide impressed analysts with a solid set of top-line results demonstrating its effectiveness--in combination with the bestselling Lantus--for controlling
Sanofi-Aventis reports PhIII success for diabetes drug
Sanofi-Aventis has gained some fresh evidence to back lixisenatide, its late-stage GLP-1 therapy for Type 2 diabetes. Researchers say that the drug improved glycemic control in patients and reduced
